|
|
|
12 February, 2013
|
| In this Issue |
Turkey: A Promise Restored?
Turkey’s pharma prospects took a significant hit after the government reacted ‘in Greece mode’ to the increased healthcare spending of the 2000s. But now the country look like it might be back on track ...Read more |
Who is Really in Charge of EU Drug Registration?
The obscure case of a French orphan drug for liver disease has escalated into a debate about who really calls the shots with regard to EU drug authorization decisions — scientific experts, or Brussels bureaucrats? Reflector reports ... Read more |
Globalization — Japanese Style
Pharm Exec looks at the trends and critical factors to consider when fostering productive relationships with Japanese companies ... Read more |
Read the New Pharm Exec Global Digest
This month’s issue: Is there a global policy gap on cancer? – What is CLM anyway? – Gamification explained – The impact of the Syrian crisis on pharma – And more ... Read more
|
|
|
|
What do you think is the main challenge facing manufacturers seeking to launch a new biosimilar?
